AbbVie Inc. (ABBV): Price and Financial Metrics

AbbVie Inc. (ABBV): $152.25

0.88 (-0.57%)

POWR Rating

Component Grades








Add ABBV to Watchlist
Sign Up

ABBV Price/Volume Stats

Current price $152.25 52-week high $168.11
Prev. close $153.13 52-week low $130.96
Day low $151.37 Volume 3,697,500
Day high $153.83 Avg. volume 5,579,785
50-day MA $149.41 Dividend yield 3.83%
200-day MA $149.74 Market Cap 268.73B

ABBV Stock Price Chart Interactive Chart >


  • Quality is the dimension where ABBV ranks best; there it ranks ahead of 96.74% of US stocks.
  • ABBV's strongest trending metric is Value; it's been moving up over the last 177 days.
  • ABBV ranks lowest in Momentum; there it ranks in the 22nd percentile.

ABBV Stock Summary

  • ABBVIE INC's market capitalization of $269,593,229,903 is ahead of 99.43% of US-listed equities.
  • ABBVIE INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 88.95% of US listed stocks.
  • In terms of volatility of its share price, ABBV is more volatile than merely 10.38% of stocks we're observing.
  • Stocks that are quantitatively similar to ABBV, based on their financial statements, market capitalization, and price volatility, are CSCO, PFE, SHEL, ADBE, and NFLX.
  • ABBV's SEC filings can be seen here. And to visit ABBVIE INC's official web site, go to

ABBV Valuation Summary

  • ABBV's price/sales ratio is 4.8; this is 20% higher than that of the median Healthcare stock.
  • Over the past 130 months, ABBV's price/sales ratio has gone up 1.6.

Below are key valuation metrics over time for ABBV.

Stock Date P/S P/B P/E EV/EBIT
ABBV 2023-09-22 4.8 21.0 31.0 26.1
ABBV 2023-09-21 4.8 21.0 31.2 26.2
ABBV 2023-09-20 4.8 21.1 31.2 26.2
ABBV 2023-09-19 4.8 21.1 31.2 26.2
ABBV 2023-09-18 4.8 21.1 31.3 26.3
ABBV 2023-09-15 4.8 20.9 30.9 26.0

ABBV Growth Metrics

    Its 4 year price growth rate is now at 25.33%.
  • Its 5 year net income to common stockholders growth rate is now at 33.69%.
  • The year over year price growth rate now stands at 32.03%.
ABBV's revenue has moved up $3.1836e+10 over the prior 70 months.

The table below shows ABBV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 58,054 24,943 11,836
2022-09-30 57,819 22,590 13,407
2022-06-30 57,349 22,923 12,637
2022-03-31 56,725 22,808 12,479
2021-12-31 56,197 22,777 11,542
2021-09-30 55,169 22,556 7,534

ABBV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABBV has a Quality Grade of B, ranking ahead of 80.75% of graded US stocks.
  • ABBV's asset turnover comes in at 0.369 -- ranking 131st of 682 Pharmaceutical Products stocks.
  • PLXP, HSTO, and ADMP are the stocks whose asset turnover ratios are most correlated with ABBV.

The table below shows ABBV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.369 0.677 0.119
2021-06-30 0.359 0.656 0.102
2021-03-31 0.335 0.648 0.078
2020-12-31 0.339 0.664 0.070
2020-09-30 0.339 0.687 0.131
2020-06-30 0.372 0.736 0.147

AbbVie Inc. (ABBV) Company Bio

Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Latest News Stream

Event/Time News Detail
Loading, please wait...

ABBV Latest Social Stream

Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as Liechtenste

Yahoo | September 25, 2023

UPDATE 1-AbbVie terminates deal with I-Mab to develop cancer drug

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab. AbbVie's decision to scrap the deal comes after it pulled the plug on an early-stage study in August last year that was testing lemzoparlimab in combination with two other drugs for treating two types of blood cancers, myelodysplastic syndrome and acute myelocytic leukemia. The deal termination will be effective Nov. 20 this year, and will not affect upfront and milestone payments of $200 million that the company has received from AbbVie, according to I-Mab.

Yahoo | September 22, 2023

20 Most Innovative Companies in America

In this article, we will take a look at the most innovative companies in America. If you want to explore similar companies, you can go to 5 Most Innovative Companies in America. Innovation and American Companies Innovation comes with new and creative ideas that bring a healthy change in society. Innovation in business and technology […]

Yahoo | September 22, 2023

AbbVie Stock Shows Rising Relative Strength Rating

On Thursday, AbbVie stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 71. See if AbbVie stock can continue to show renewed price strength and hit that benchmark. Is AbbVie Stock A Buy?

Yahoo | September 21, 2023

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).

Yahoo | September 21, 2023

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo 3.16%
3-mo 14.26%
6-mo -2.52%
1-year 9.56%
3-year 98.31%
5-year 103.46%
YTD -2.96%
2022 24.01%
2021 32.43%
2020 27.72%
2019 1.47%
2018 -0.96%

ABBV Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!